Interpharm Biotech Private Limited - Due diligence report

A 360° intelligence report on Interpharm Biotech: trust score, financial health, credit view, compliance, directors, growth and distress sig…

1999-10-20 Vadodara, Gujarat Active Unlisted Active Compliant
Share
Connect MCP
IB Interpharm Biotech Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Interpharm Biotech — 360° Intelligence Report

Generated from MCA filings & public records
67/100
Trust Score
Moderate

Interpharm Biotech is assessed as Moderate with a Trust Score of 67/100. Interpharm Biotech is an active private limited indian non-government company incorporated in 1999, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 13 Aug 2026 from the latest processed filings. Interpharm Biotech Private Limited snapshot & full profile →

Financial Health › Caution
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
67/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
85/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
20/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
50/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
55/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.

Charges position: 0 open (-) · 1 satisfied (45.00 Lakh).

Banking relationships (from registered charges)
LenderChargesAmount
Bank Of Baroda1 48.0 cr
Compliance Score: 85/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 1 court forum(s).
  • Delayed payments to MSME suppliers disclosed (3 disclosure(s)).
  • 1 active GST registration(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
SUDIP CHAKRABORTY 01234567 Director 01/04/2018 6 yrs Approved
SAMIR CHAKRABORTY 01234567 Director 01/04/2018 6 yrs Approved
SANKALP PRADEEP AGRAWAL 01234567 Director 01/04/2018 6 yrs Approved
SUNITA PRADEEP AGRAWAL 01234567 Director 01/04/2018 6 yrs Approved
PRADEEP VISHAMBHAR AGRAWAL 01234567 Director 01/04/2018 6 yrs Approved
  • 5 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2022 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
1 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 50 · Distress 55
Growth signals & trust indicators
Latest year revenue grew 38%.
Operating for 26+ years.
Active GST registration(s).
Distress signals & risk flags
Losses deepening year-on-year.
Negative net worth.
MSME payment delays disclosed - latest outstanding 1.65 Lakh.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence71/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment48/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view44/100
Limited indicators at present
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
30 Sep 2019
Director ceased
SUNITA PRADEEP AGRAWAL
15 Oct 2018
Director appointed
SUNITA PRADEEP AGRAWAL (Director)
30 Sep 2015
Director ceased
SUDIP CHAKRABORTY
Director ceased
SAMIR CHAKRABORTY
Director ceased
SANKALP PRADEEP AGRAWAL
06 Jan 2015
Director appointed
SUDIP CHAKRABORTY (Director)
Director appointed
SAMIR CHAKRABORTY (Director)
Director appointed
SANKALP PRADEEP AGRAWAL (Director)
30 Mar 2013
Securities allotted
500000.00 Equity Shares - 50.00 Lakh raised
29 Sep 2012
Director ceased
PRADEEP VISHAMBHAR AGRAWAL
18 Apr 2012
Charge satisfied
Bank Of Baroda
21 Feb 2012
Director ceased
SANJAY KAPOOR
Director ceased
MAGAN KHANDUBHAI JADHAV
10

Key Observations

Auto-generated from the data above
Revenue declined 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Compliance record is strong - status, filings and flags are clean.
5 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
All 1 registered charge(s) stand satisfied - past borrowings repaid.
Promoters hold a dominant controlling stake as per the FY 2022 annual return.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Lakshmi Abrasives Private Limited U65921UP1985PTC007319 Uttar Pradesh, Uttar Pradesh, India
Aatmos Pharma (Opc) Private Limited U51909HR2015OPC055667 Karnal, Haryana, India
Kapsin Pharma Private Limited U24299GJ2016PTC092322 Ahmedabad, Gujarat, India
Visesh Ayurved India Private Limited U24233KL1995PTC009060 Kottayam, Kerala, India
Vishal Dentocare Private Limited U24231GJ2001PTC040316 Ahmedabad, Gujarat, India
Medigrand Pharmaceuticals Private Limited U24297TN2011PTC081348 Harur, Tamil Nadu, India
Phytobiox Manufactures Private Limited U01100OR2017PTC027968 Bhubaneswar, Orissa, India
Senable Life Sciences Private Limited U74999RJ2017PTC058001 Jaipur, Rajasthan, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Interpharm Biotech before audits and certifications: compliance score 85/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Interpharm Biotech: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Limited indicators at present. Growth score 50/100, margin trends, ownership structure and peer set for Interpharm Biotech - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 67/100, distress signals and MSME payment-delay disclosures - know whether Interpharm Biotech pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Interpharm Biotech - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Interpharm Biotech an active company?

Interpharm Biotech has MCA status “Active” with a compliance score of 85/100 (Low Risk).

Is Interpharm Biotech financially healthy?

Interpharm Biotech has a Financial Health Score of 20/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Interpharm Biotech?

Its overall Trust Score is 67/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Interpharm Biotech?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 5 active director(s) are on record.

Does Interpharm Biotech have loans or charges against its assets?

No open charges - all 1 registered charge(s) stand satisfied, indicating past borrowings were repaid.

Is Interpharm Biotech up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 85/100 (Low Risk).

Is it risky to lend to Interpharm Biotech?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.